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Abstract Following extensive examination of pub-
lished and unpublished materials, we provide a history
of the use of dexamethasone in pregnant women at risk
of carrying a female fetus affected by congenital adrenal
hyperplasia (CAH). This intervention has been aimed at
preventing development of ambiguous genitalia, the
urogenital sinus, tomboyism, and lesbianism. We map
out ethical problems in this history, including: mislead-
ing promotion to physicians and CAH-affected families;
de facto experimentation without the necessary protec-
tions of approved research; troubling parallels to the
history of prenatal use of diethylstilbestrol (DES); and
the use of medicine and public monies to attempt
prevention of benign behavioral sex variations. Critical
attention is directed at recent investigations by the U.S.
Food and Drug Administration (FDA) and Office of
Human Research Protections (OHRP); we argue that
the weak and unsupported conclusions of these inves-
tigations indicate major gaps in the systems meant to
protect subjects of high-risk medical research.
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Introduction/Our Backgrounds
In this article, we provide a condensed history of the use
of prenatal dexamethasone for congenital adrenal hyper-
plasia, with an eye toward the ethically problematic
aspects of this history. Congenital adrenal hyperplasia
(CAH) is a disease of the endocrine system that can
cause virilization (i.e., development of masculine traits)
in female fetuses. In an attempt to prevent CAH-affected
female fetuses from developing in a sexually atypical
fashion, some physicians treat pregnant women “at risk”
for having an affected daughter with the steroid dexa-
methasone. This intervention starts as soon as pregnan-
cy is confirmed and continues throughout the pregnancy
if the fetus is ultimately diagnosed as a CAH-affected
female. If—several weeks into the dosing—the fetus is
determined to be male or not CAH-affected, the inter-
vention is immediately stopped, because the intention is
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only to alter the course of development in CAH-affected
females.
Thisuseof dexamethasonewas first described in1984
inTheJournalofPediatricsbyMichelDavidandMague-
loneForest, French clinician-researchers.David andFor-
est reported apparent effectiveness of prenatal
dexamethasone in eliminating genital virilization in a
single girl affected by CAH (David and Forest 1984). In
the nearly three decades since David and Forest’s paper,
many specialists have come to believe that prenatal dexa-
methasone for CAH constitutes the standard of care. A
2000–2001 survey of members of the European Society
for Paediatric Endocrinology, representing 125 institu-
tions, found that, “[i]n 57 % of the centres prenatal diag-
nosis and treatment [of CAH with dexamethasone] are
routine” (Riepe et al. 2002, 199). A 2010 Continuing
Medical Education review article in the Obstetrical and
Gynecological Survey concluded: “Given the data avail-
able at this moment, antenatal treatment with corticoste-
roids is recommended” (Vos and Bruinse 2010, 203).
But what data are “available at this moment” such
that prenatal dexamethasone for CAH can be recom-
mended to obstetricians, and recommended by them to
prospective patients?
A systematic review and meta-analysis of this inter-
vention, published in 2010 in Clinical Endocrinology,
indicated that a search of the literature “identified 1083
candidate studies for review; of which, only four studies
were confirmed eligible” for serious scientific consider-
ation (Fernández-Balsells et al. 2010, 438). That is to say,
as late as 2010, less than one half of one percent of
published “studies” of this intervention were regarded
as being of high enough quality to provide meaningful
data for a meta-analysis. Even these four studies were of
low quality:
All the eligible studies were observational and
were conducted by two groups of investigators
(one from the US and one from Europe).… Stud-
ies lacked details regarding the use of methodo-
logical features that protect against bias. None of
the studies reported blinding of the outcome asses-
sors to the exposure (i.e., the researchers estimat-
ing each patient’s degree of virilization). Loss to
follow-up was, in most cases, substantial
(Fernández-Balsells et al. 2010, 438).
In spite of at least a thousand pregnant women
likely having been exposed by the time of the review,
the four studies judged worthy of inclusion in the
meta-analysis covered only 325 pregnancies. Even
more stunning, the meta-analysis revealed, “there
were no data on long-term follow-up of physical and
metabolic outcomes in children exposed to dexameth-
asone” prenatally for CAH (Fernández-Balsells et al.
2010, 436, emphasis added). It was not that the data
about long-term physical and metabolic outcomes
were unclear; there simply were none available.
Today, some clinicians promote prenatal dexametha-
sone for CAH as “an excellent example of pharmaco-
logical therapy during pregnancy” (Rosner et al. 2006,
803) and even as “a paradigm of prenatal diagnosis and
treatment” (Nimkarn and New 2010a, 5). Yet the Endo-
crine Society Task Force that had commissioned the
2010meta-analysis concluded: “The evidence regarding
fetal and maternal sequelae … is of low or very low
quality due to methodological limitations and sample
sizes” (Speiser et al. 2010a, 4137). This would hardly
seem to qualify prenatal dexamethasone for CAH as “an
excellent example” or a “paradigm” of a prenatal phar-
macological intervention. Indeed, for lack of quality
clinical studies, the 2010 Task Force could not even
say with any confidence whether prenatal dexametha-
sone works to reduce genital virilization. Notice the
specific qualifications included in the Task Force’s state-
ment on efficacy: “[T]he groups advocating and
performing prenatal treatment appear to agree that it
is effective in reducing and often eliminating virilization
of female fetal genitalia and that the success rate is about
80–85%” (Speiser et al. 2010a, 4138, emphasis added).
Regardless of some people’s enthusiastic endorse-
ments of the intervention, we show below that ethical
debates within medicine about prenatal dexametha-
sone for CAH are actually not new. Those internal
debates, however, have focused on potential risks
and benefits to mothers and children exposed. There
are a number of other ethical problems in the history of
this intervention also deserving of attention, including:
de facto experimentation on fetuses and pregnant
women, largely outside of prospective long-term trials
and without adequate informed consent; failure to
appropriately collect and publish evidence when pro-
moting and providing a high-risk intervention; use of
medicine and public monies for research to prevent
benign behavioral sex variations, including tomboy-
ism and lesbianism (cf. Murphy 1997); and inadequa-
cy in the United States of systems designed to protect
subjects of medical experimentation, including espe-
cially pregnant women and their offspring.
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In the United States, the use of prenatal dexametha-
sone remains “off-label.” This means that the indication
has never received approval by the Food and Drug
Administration (FDA).1 Nonetheless, we want to be
clear: The problem we see with the use of prenatal
dexamethasone for CAH is not per se that it is an off-
label use; it is rather that—as this paper documents—
prenatal dexamethasone for CAH has sometimes been
promoted to prospective patients and clinicians in mis-
leading ways, and sometimes promoted for uses that are
not legitimately medical (e.g., for the prevention of
tomboyism and lesbianism). Furthermore, this interven-
tion—intended to alter the course of fetal development
—has been “studied” in ways so slipshod as to breach
professional standards of medical ethics.
We come to this work as history, philosophy, and
legal scholars interested in the medical treatment of
children with atypical sex, but also as women who have
long advocated clinical reform in this general area. Late
in 2009, clinicians working in the pediatric care of
children born with sex anomalies made one of us
(Dreger) aware of their growing alarm about prenatal
dexamethasone for CAH. These clinicians were
concerned that pregnant women at risk for having
daughters with CAH were being given prenatal dexa-
methasone without being informed that (a) this use has
consistently been labeled experimental by expert panels;
(b) benefits and risks have not been established, due to
inadequate scientific study; and (c) some children who
had been exposed in utero were being studied retrospec-
tively, in many cases years later, by the very clinicians
who had been (andwere still) actively promoting the use
to pregnant women as “safe for mother and child,” to
find out what the risks might really be.
Dreger (a historian) then reviewed the medical lit-
erature as well as Internet-based advertisements direct-
ed at affected families and became quite concerned. In
December 2009 and January 2010, respectively,
Dreger and UCLA pediatric geneticist Eric Vilain
separately asked Mount Sinai School of Medicine
pediatric endocrinologist Maria New, the most prom-
inent promoter of this intervention, about the informed
consent process she used. New is a highly distin-
guished pediatric endocrinologist and member of the
National Academy of Sciences. By 2003, she had
already publicly taken credit for having “treated”more
than 600 pregnant women with dexamethasone in an
attempt to prevent virilization in CAH-affected female
fetuses (Kitzinger 2003), putting her efforts in this area
well beyond any other clinical researcher’s (see also
New et al. 2001). Dreger’s preliminary research indi-
cated that, even while obtaining a federal grant prom-
ising to determine the actual safety and efficacy of
prenatal dexamethasone for CAH through retrospec-
tive follow-up studies, New was functioning as a
uniquely aggressive promoter of the intervention
among parents and clinicians, repeatedly describing
this intervention as “safe for mother and child” (New
2010a, ¶4). But when Dreger and Vilain attempted to
ask New about informed consent, both were rebuffed
by New. Indeed, at the Miami medical conference
session where Vilain pressed the issue (at New
2010b), New publicly admonished Vilain that his
question to her was inappropriate.
Dreger then asked colleagues in bioethics and allied
fields to join with her in raising concerns to the U.S.
government regarding the potential failure to protect the
rights of these women and their offspring. The second
author of this paper (Feder) became the corresponding
author on the resulting (February 2010) letters of con-
cern from a total of 32 academicians to the Office of
Human Research Protections (OHRP) and the FDA.
The third author (Tamar-Mattis) handled most of our
subsequent communications with federal agencies and
conducted additional legal research.
In September 2010, the OHRP and FDA informed
us they could find nothing worth pursuing further. The
OHRP decided that abuse had not occurred because:
(a) at least some of the pregnant women had been
enrolled in IRB-approved studies when given the drug
at Weill Cornell Medical College, where most of the
interventions appear to have occurred while New
worked there; (b) follow-up studies conducted at
Mount Sinai School of Medicine under New had been
IRB-approved; and (c) the fetal intervention itself does
not require IRB oversight. The FDA explained that (to
our surprise) regulations allow a clinician to promote
an off-label use—even an experimental use intended
to alter fetal development—as “safe and effective” so
long as the clinician does not simultaneously work for
the drug maker or count as an FDA-approved investi-
gator of the drug (Borror 2010). (Dreger has made the
agencies’ full responses available at fetaldex.org.)
Nevertheless, we show here that the material generat-
ed by the government’s own investigations—along
1 For an analysis of the problems with off-label usages, see
Dresser and Frader (2009).
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with further scholarly inquiry on our part—appear
actually to confirm the concerns we expressed at the
outset, suggesting a major failure of the layered sys-
tems designed to protect subjects of research, especial-
ly pregnant women and their fetuses.
Because the following history necessarily focuses
attention on the actions of Maria New, we want to be
sure that our readers appreciate that New’s career has
included critically important research and clinical care
that has improved the lives, health, and fertility of a very
large population. Her promotion of prenatal dexameth-
asone for CAH was no doubt motivated by a desire to
improve the lives of her patients. The same beneficent
attitude was likely present in all or most of the clinicians
who used prenatal dexamethasone for CAH. But it is
worth remembering that many cases in the history of
medicine now rightly understood as ethically problem-
atic were carried out by clinical researchers with good
intentions (Eder 2011; Reverby 2009; Skloot 2010).
It has been impossible for us not to be aware that, as
we have researched this fetal intervention, the medical
world has beenmarking the 40th anniversary of the 1971
publication of a study reporting a relatively high number
of occurrences of a rare vaginal cancer in girls and
young women who had been exposed in utero to dieth-
ylstilbestrol (DES). It was this small 1971 study—eight
subjects with adenocarcinoma of the vagina matched to
32 untreated controls—that marked the beginning of the
end of DES administration to pregnant women (Herbst,
Ulfelder, and Poskanzer 1971). DES treatment during
pregnancy had had admirable intentions, including pri-
marily the prevention of miscarriage. Already by 1953,
DES had actually been found ineffective for miscarriage
prevention, but doctors continued to prescribe it to preg-
nant women anyway. Over the years, millions of fetuses
were exposed, putting females and males at increased
risk for rare cancers, genital anomalies, reproductive
problems, etc. (Goodman, Schorge, and Greene 2011).
As we have spoken with others about how the use of
prenatal dexamethasone for CAH has played out, it has
been our experience that many have been skeptical that a
DES-like scenario could occur with prenatal dexametha-
sone for CAH after what physicians learned from DES.
Wefindourselveswonderingwhether it is theassumption
that “we’ll never do that again” that paradoxically has
blinded many clinicians to the striking parallels between
DES and prenatal dexamethasone for CAH: Both DES
and dexamethasone are powerful synthetic hormones; in
both cases the practice involved administration of the
intervention starting early in pregnancy; both were intro-
duced into medical practice without much study as to
efficacy and safety (Dreger et al. forthcoming).
Three strikingdifferencesbetween these interventions
are that: (1) this poorly studied yet widespread use of
prenatal dexamethasone is happening after the lessons
supposedly learned fromDES; (2) while DES was never
intended to alter fetal development, prenatal dexametha-
sone forCAHhas explicitly aimed to do so; and (3)while
DESwas aimedatpreventing fetal death,dexamethasone
is directed at preventing something we would hopemost
people would understand to be substantially less dire,
namely the development of atypical sex.
Yet rather than suggesting that the case of prenatal
dexamethasone for CAH should be understood as one
of the “big” stories of the history of medicine (like
DES), we are suggesting something more disturbing:
that this case appears to be representative of problems
endemic in modern medicine, problems that threaten
the health, lives, and rights of patients who continue to
become unwitting subjects of (problematic) medical
experimentation. Because so many systems of protec-
tion appear to have failed these women and children,
we fear that prenatal dexamethasone for CAH is a
canary in the modern medical mine.
CAH’s Effects and the Goals of Using Prenatal
Dexamethasone
Congenital adrenal hyperplasia (CAH) is a genetic
disease involving malfunction of the adrenal glands,
endocrine organs that contribute to the production of
sex steroids. CAH can occur in both males and
females and can cause a number of metabolic prob-
lems, some of which may lead to postnatal adrenal
crisis and death if left untreated. Because some forms
of CAH are very dangerous, all U.S. states require
newborn screening for CAH.
The prenatal administration of dexamethasone, a po-
tent synthetic steroid of the glucocorticoid class, cannot
prevent an affected child from being born with CAH.
The intervention is aimed instead at causing CAH-
affected female fetuses to develop in a more female-
typical fashion than they otherwise might. Androgens
contribute to sex differentiation, including in the brain
and genitals; relatively low prenatal levels ordinarily
result in a more female-typical development; relatively
high levels usually result in male-typical development.
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In certain forms of CAH—including 21-hydroxylase
deficiency (21-OHD CAH), i.e., the type of CAH most
at issue here—the prenatal production of high levels of
androgens may result in a genetic female (46,XX) fetus
developing along a more masculine pathway neurolog-
ically and genitally. Prenatal dexamethasone is meant to
engineer the CAH-affected female fetus’s hormonal
system to be typically female.
The intensity of CAH’s effects on developing females
varies. An affected genetic-female child might be born
fairly female-typical, or she may be born with a large
clitoris, labia that fuse and appear to form a scrotum,
and an occluded or even absent lower vagina. Some
affected genetic females have developed suchmasculine
genitalia that theyhavebeenassumedatbirth tobe typical
males and have been raised as boys (Eder 2011; Lee and
Houk2010).Newbornscreening forCAH,aimedprimar-
ily at saving lives, has greatly reduced the likelihood of
such children’s conditions going undetected.
Atypical clitorises and labia generally require nomed-
ical intervention for health.Despite evidence that elective
genitoplasty may harm a girl (Crouch et al. 2004), pedi-
atric urologists often perform surgery to “feminize” atyp-
ical clitorisesand labia forwhat theycall“social reasons,”
includingpromotionofparent–childbonding.Theydoso
evenwhile admittingwe lack evidence that this approach
is necessary or effective (Lee et al. 2006).
Some CAH-affected girls are also born with a uro-
genital sinus, a condition in which the urethra and
vagina are joined together. This creates potential for
repetitive infections and also presents problems for sex-
ual intercourse. Thus the urogenital sinus has tradition-
ally been treated with pediatric surgery. It represents part
of what prenatal dexamethasone is meant to prevent.
Women “at risk” of giving birth to a CAH-affected
daughter are most often identified because they have
already given birth to a CAH-affected child. Others are
identified through genetic screening. Because “the peri-
od during which the genitalia of a female fetus may
become virilized begins only 6 [weeks] after concep-
tion, treatment must be instituted as soon as the woman
knows she is pregnant” (Speiser et al. 2010a, 4137; cf.
Nimkarn and New 2007). Although this intervention is
sometimes termed “low-dose therapy” (New 2010c),
researchers estimate that “the effective glucocorticoid
doses reaching the fetus are 60–100 times physiologic”
(Miller 2008, 17), meaning this intervention exposes the
developing fetus to 60 to 100 times the normal level of
glucocorticoids. The potential harms of prenatal
dexamethasone represent a growing source of concern
for clinical researchers because emerging research indi-
cates glucocorticoids may alter “fetal programming,”
potentially resulting in serious metabolic problems that
will not become apparent until adulthood (Hirvikoski et
al. 2007; Marciniak et al. 2011). Some animal studies,
for example, suggest long-term risk to the cardiovascu-
lar system (Lajic, Nordenström, and Hirvikoski 2011).
CAH is an autosomal recessive disorder, so offspring
of carrier parents have a 1 in 4 chance of having CAH
and thus only a chance of 1 in 8 of being a CAH-affected
female (since only half of the 1 in 4 will be females).
While recent advances now may enable determination
of fetal sex by the seventh week (Devaney et al. 2011),
before 2011 the sex status of fetuses could not be deter-
mined reliably before 10 to 12 weeks. As a conse-
quence, about 7 out of 8 (87.5 percent) of the
individuals who have been exposed to many weeks of
prenatal dexamethasone—at 60 to 100 times normal
levels—never even had the condition that was being
targeted with the prenatal intervention. These individu-
als have been “necessarily” exposed to risk in order to
try to engineer the development of the 1 in 8 who would
be CAH-affected females. Many of the clinicians who
have raised ethical concerns about prenatal dexametha-
sone for CAH have specifically been concerned about
the 87.5 percent (those 7 out of 8) exposed to the risk of
first-trimester glucocorticoid “therapy” who stood no
chance to benefit (e.g., Frias et al. 2001; Hirvikoski et
al. 2007; Miller 2008; Speiser et al. 2010a).
Most clinicians who have written about prenatal
dexamethasone have spoken of its purpose as the
prevention of ambiguous genitalia and the urogenital
sinus. (Sometimes they speak of the urogenital sinus
as part of “ambiguous genitalia,” and sometimes they
speak of these as two sets of concerns.) But interest-
ingly, some clinicians also speak of prenatal dexame-
thasone’s purpose as the prevention of feminizing
genital surgeries. So one elective risky intervention
(prenatal dexamethasone) has been represented as nec-
essary to prevent another (feminizing genital surger-
ies) (Nimkarn and New 2010a). Notably, in 2006, a
major consensus of the American and European pedi-
atric endocrine groups, known as “the Chicago con-
sensus,” urged a more conservative approach to
surgeries for genital anomalies, stating that, for girls,
“surgery should only be considered in cases of severe
virilization” (Lee et al. 2006, e491). But this recom-
mendation does not appear to have had much (if any)
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effect on the promotion of prenatal dexamethasone as
a preventive to “feminizing” surgery.
Studieshaveshownthatgirlswith21-OHDCAHexhibit
increased ratesofwhat clinicians call“behavioralmasculin-
ization,” i.e., behaviors that are more male-typical. These
girls are, on average, more interested in boy-typical play,
hobbies, and subjects than non-affected females, less inter-
ested in becomingmothers, andmore likely to grow up to
be lesbian or bisexual (Meyer-Bahlburg 1999; Meyer-
Bahlburg et al. 2006). The rate of adult identification as
male is significantly higher in this group than in the
general population of people with an XX karyotype;
clinician-researchers report that about 5 percent of
CAH-affected genetic-females may ultimately self-
identify as male (Dessens, Slijper, and Drop 2005).
For this reason, some clinicians have considered recom-
mending raising highly virilized 46,XX CAH-affected
babies as boys (Lee and Houk 2010; cf. Eder 2011).
Although many researchers have hinted that prenatal
dexamethasonemight be good for preventing the “behav-
ioralmasculinization” associatedwithCAH (e.g., Lajic et
al.1998), thispotential“benefit”hasbeenspelledoutmost
explicitly in the work of Maria New (Dreger, Feder, and
Tamar-Mattis 2010).Writingwith another pediatric endo-
crinologist in the2010Annalsof theNewYorkAcademyof
Sciences in an article that disregarded the 2006 Chicago
consensus, New summed up the situation thus:
Without prenatal therapy, masculinization of ex-
ternal genitalia in females is potentially devastat-
ing. It carries the risk of wrong sex assignment at
birth, difficult reconstructive surgery, and subse-
quent long-term effects on quality of life. Gender-
related behaviors, namely childhood play, peer
association, career and leisure time preferences
in adolescence and adulthood, maternalism [inter-
est in being a mother], aggression, and sexual
orientation become masculinized in 46,XX girls
and women with 21HOD deficiency. … Genital
sensitivity impairment and difficulties in sexual
function in women who underwent genitoplasty
early in life have likewise been reported. We an-
ticipate that prenatal dexamethasone therapy will
reduce the well-documented behavioral masculin-
ization and difficulties related to reconstructive
surgeries (Nimkarn and New 2010a, 9).
Among those advocating prenatal dexametha-
sone, New seems to have been particularly
concerned that CAH-affected girls may fail to
grow up to be heterosexual wives and mothers.
Speaking to a group of parents of children with
CAH in 2001 at a meeting organized by the
CARES Foundation, New showed a photo of a
girl with ambiguous genitalia and said:
The challenge here is … to see what could be
done to restore this baby to the normal female
appearance which would be compatible with her
parents presenting her as a girl, with her eventu-
ally becoming somebody’s wife, and having nor-
mal sexual development, and becoming a
mother. And she has all the machinery for moth-
erhood, and therefore nothing should stop that, if
we can repair her surgically and help her psy-
chologically to continue to grow and develop as
a girl (New 2001a).
In a 1999 paper entitled “What Causes Low Rates
of Child-Bearing in Congenital Adrenal Hyperpla-
sia?”, New’s chief collaborator in psychoneuroendo-
crine studies of CAH, Heino Meyer-Bahlburg of
Columbia University, noted:
CAH women as a group have a lower interest
than controls in getting married and performing
the traditional child-care/housewife role. As
children, they show an unusually low interest
in engaging in maternal play with baby dolls,
and their interest in caring for infants, the fre-
quency of daydreams or fantasies of pregnancy
and motherhood, or the expressed wish of expe-
riencing pregnancy and having children of their
own appear to be relatively low in all age
groups. (Meyer-Bahlburg 1999, 1845–1846).
Meyer-Bahlburg posited that “[l]ong term follow-
up studies of the behavioral outcome will show wheth-
er [prenatal] dexamethasone treatment also prevents
the effects of prenatal androgens on brain and behavior”
(1999, 1846).
Surprisingly, results from our Freedom of Informa-
tion Act (FOIA) requests—made as part of our attempt
to understand this history—indicate that the U.S. Na-
tional Institutes of Health (NIH) have fundedNew to see
whether prenatal dexamethasone “works” to make more
CAH-affected girls straight and interested in having
babies. New’s 1996 grant application states that
genital abnormalities and often multiple correc-
tive surgeries needed affect social interaction,
self image, romantic and sexual life, and fertility.
282 Bioethical Inquiry (2012) 9:277–294
As a consequence, many of these patients, and the
majority of women with the salt-losing variant [of
CAH], appear to remain childless and single. Pre-
ventive prenatal dexamethasone exposure is
expectedto improve thissituation(New1996a,38).
New’s NIH grant application specifically promised
to try to determine “the success of DEX in suppressing
behavioral masculinization” (New 1996b, 17).
A Long History of Ineffective Calls for Ethical,
Scientifically Rigorous Studies
The 2010 systematic review and meta-analysis of pre-
natal dexamethasone for CAH (mentioned in our intro-
duction) was commissioned by an Endocrine Society
Task Force charged with developing new consensus
guidelines for the treatment of CAH. That Task Force
was in turn co-sponsored by the American Academy of
Pediatrics, the Lawson Wilkins Pediatric Endocrine So-
ciety, the European Society for Paediatric Endocrinolo-
gy, the Society of Pediatric Urology, the European
Society of Endocrinology, the CARES Foundation,
and the Androgen Excess and PCOS Society. Based
on the systematic review and meta-analysis, in its 2010
practice guidelines the Task Force concluded
that prenatal therapy continue to be regarded as
experimental. … We suggest that prenatal thera-
py be pursued through protocols approved by
Institutional Review Boards [i.e., ethics commit-
tees] at centers capable of collecting outcomes
data on a sufficiently large number of patients so
that risks and benefits of this treatment can be
defined more precisely (Speiser et al. 2010a,
4137, emphasis added).
The named authors of this 2010 consensus (includ-
ing Meyer-Bahlburg) appeared to have recognized that
their call for use only within scientifically-meaningful
clinical trials pre-approved by ethics committees was
not novel. In fact, expert panels have consistently
judged prenatal dexamethasone for CAH to be risky
and experimental. In 2002, a joint statement from the
Lawson Wilkins Pediatric Endocrine Society and the
European Society for Paediatric Endocrinology had
already said something similar—even stronger:
We believe that this specialized and demanding
therapy should be undertaken by designated
teams using nationally or multinationally ap-
proved protocols, subject to institutional review
boards [IRBs] or ethics committees in recog-
nized centers. Written informed consent must
be obtained. … Families and clinicians should
be obliged to undertake prospective follow-up of
prenatally treated children whether they have
CAH or not. The data should be entered into a
central database audited by an independent safety
committee. (Joint LWPES/ESPE CAH Working
Group 2002, 4049, emphasis added).
And a year earlier, in a tense exchange of letters
with New in the journal Pediatrics, representatives of
the Section on Endocrinology and Committee on Ge-
netics of the American Academy of Pediatrics had
admonished New that
it remains the physician’s ethical obligation to
remain very cautious, even if using lower doses.
The fact that only 1 in 8 treated pregnancies may
benefit from the therapy confounds this equation
even further. There is much information on the
effect of glucocorticoids on the brain. Data con-
tinue to accumulate that indicate that high-dose
glucocorticoid therapy is harmful for the devel-
oping (prenatal and postnatal) brain. Further, Dr.
New herself coauthored a paper reporting in-
creased frequency of white matter abnormalities
and temporal lobe atrophy on magnetic reso-
nance imaging in patients with CAH. Although
cause and effect remain to be established, one
must consider that glucocorticoid therapy may
have played a role in causing these abnormalities
(Frias et al. 2001, 805).
The AAP Committee concluded, in their response
to New:
The maxim of “first do no harm” requires a cau-
tious, long-term approach, which is why the Acad-
emy Committee unanimously agrees that prenatal
glucocorticoid therapy for CAH should be con-
fined to centers doing controlled prospective,
long-term studies. The memory of the tragedies
associated with prenatal use of dexamethasone
and thalidomide demands no less (Frias et al.
2001, 805, emphasis added).
A few months later, Pediatrics issued an erratum, cor-
recting what may have been a Freudian slip; the AAP
Committee hadmeant to say “thememory of the tragedies
associatedwith the prenatal use of diethylstilbestrol (DES)
Bioethical Inquiry (2012) 9:277–294 283
and thalidomidedemandsno less” (Pediatrics2001, 1450,
emphasis added).
Over the years, many individual researchers and
clinicians expressed similar concerns about the use of
prenatal dexamethasone for CAH outside of appropriate
studies or, in some cases, about its use at all (Seckl and
Miller 1997; Miller 1999; Ritzen 2001; Hughes 2003;
Lajic et al. 2004; Hirvikoski et al. 2007). Even Forest,
the French pioneer of the intervention, wrote in 2004,
“the prenatal treatment of CAH remains an experimental
therapy and, hence, must only be done with fully in-
formed consent in controlled prospective trials approved
by human experimentation committees at centre’s that
see enough of these patients to collect meaningful data”
(2004, 479, emphasis added). By 2008, Walter Miller,
distinguished professor of pediatrics and chief of endo-
crinology at the University of California–San Francisco,
declared, “It is this author’s opinion that this experimen-
tal treatment is not warranted and should not be pursued,
even in prospective clinical trials” (Miller 2008, 17).
Miller later would add: “It seems to me that the main
point of prenatal therapy is to allay parental anxiety. In
that construct, one must question the ethics of using the
fetus as a reagent to treat the parent, especially when the
risks are non-trivial” (in Dreger 2010, ¶20).
In spite of all these challenges and warnings, New
and her collaborators in the United States appear never
to have entered into a prospective, long-term, contin-
uous study of the use of prenatal dexamethasone for
CAH. New and her group do appear to have occasion-
ally done some trials of prenatal dexamethasone dur-
ing pregnancy, tracking outcomes up to the birth;
among the 325 pregnancies included in studies seri-
ously considered by the 2010 meta-analysis, 281 came
from New’s group (Fernández-Balsells et al. 2010).
Even those, however, were not studied in a matter
adequate to establish efficacy or safety according to
the standards of evidence-based medicine. The trials
lacked adequate controls and methods to mitigate bias.
Moreover, our recent FOIA findings on New’s
pregnancy trials of dexamethasone throw up multiple
ethical red flags. For example, in her 1985 application
to the Cornell IRB to study prenatal dexamethasone
for CAH, New did not check the boxes indicating that
her subject population included pregnant women and
fetuses (New 1985, 2), even while, deeper in the
application, she indicates that the study design calls
for administration of dexamethasone starting at two to
four weeks of gestation (New 1985, 9e). The
accompanying consent form describes this use as exper-
imental, but then goes on to minimize the risks:
I understand that my participation in the project
involves the following risks: transient and revers-
ible suppression of the maternal and fetal adrenal
gland. For this reason, extra doses of steroids will
be administered to the mother at the time of deliv-
ery to cover for the additional stress. Although
complications of glucocorticoid therapy (cleft pal-
ate, growth retardation, placental degeneration
and fetal death) have been reported in laboratory
animals, the doses used were extremely high.
Congenital malformations associated with dexa-
methasone therapy are rare in humans, even when
large doses are given. The pregnant women and
fetuses treated to date with this regimen have not
experienced complications (New 1985, 9e).
Apregnantwomanreading thismight reasonablyhave
read “transient and reversible” to mean that the risks
included no long-term harms to her or her offspring.
In another New York Presbyterian Hospital/Cornell
Weill Medical College consent form for the prenatal
administration of dexamethasone for CAH, marked
“IRB Approved” and dated April 2004, New required
pregnant women to sign a form saying they under-
stood the use was “experimental.” But the form also
advised the women: “Over the last decade, treatment
with dexamethasone in the prescribed doses has been
shown to be effective in reducing the masculinization
of the female fetus with CAH and has been shown to
be safe for the fetus” (New 2004).
Thus, it remains unclear—but doubtful—whether
U.S. federal regulation 45 CFR 46 subpart B,
which regulates experimentation on pregnant wom-
en, was consistently followed in this use of prenatal
dexamethasone. Because the OHRP removed, from
its FOIA response to us, sections of its correspon-
dence with Weill Cornell that might have indicated
how many women were included in pregnancy
trials of prenatal dexamethasone conducted by
New, we have been unable to determine how many
of the 600-plus pregnant women and fetuses she
says she had “treated” at Weill Cornell by 2003 had
the benefit of IRB surveillance (such as it was).
What we do know is that, given what we have
seen, even those engaged in IRB-approved trials
at Weill Cornell apparently cannot be said to have
given informed consent.
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So far as we can ascertain, there has been and remains
an absence of IRB oversight for prenatal dexamethasone
administration for CAH at Mount Sinai, where New
began working in June 2004, in spite of the fact that
New has claimed the exposure of fetuses at Mount Sinai
as evidence of her research progress there. For example,
in her 2006 grant “progress report” to the NIH, New
indicated that she and her team had settled in at Mount
Sinai and had been continuing the intervention there:
“The prenatal diagnosis and treatment program has gal-
loped ahead so that we now have diagnosed and or
treated 768 fetuses,” including 27 fetuses exposed to
dexamethasone from February 2005 to January 2006,
i.e., when she was at Mount Sinai (New 2006, 3).
Our FOIA digging also turned up a 2004 letter from
Jeffrey Silverstein, chair of the Mount Sinai IRB, assur-
ing the NIH that New hadMount Sinai IRB approval for
a project called “Prenatal Diagnosis and Treatment”
(Silverstein 2004); the accompanying documents indi-
cate that the project specifically involved the use of
prenatal dexamethasone for CAH. (New probably need-
ed this IRB approval letter to continue her NIH fund-
ing.) Yet in his 2010 response to the OHRP on behalf of
Mount Sinai in response to our letters of concern, Silver-
stein indicated that Mount Sinai did not believe IRB
oversight of the decision to undertake this fetal inter-
vention was needed, because New was not herself writ-
ing the prescriptions (Silverstein et al. 2010).
Mount Sinai’s 2010 conclusions that New had not
been doing research on those pregnancies appears to be
based on the confusing premise that other doctors had
been doing the prescribing to the pregnant women
whose fetuses were then included in the growing numb-
ers of New’s subjects. Perhaps Mount Sinai’s respond-
ents to the OHRP in 2010 did not know that New had
been reporting statistics on fetal exposure as part of the
federally-funded research progress she described to the
NIH as “gallop[ing] ahead” at Mount Sinai? But surely
Silverstein, who lead-authored the Mount Sinai defense
in 2010, should have known that he had himself assured
the government in 2004 that New was intending prena-
tal exposure as part of a study supposedly under IRB
supervision. If these fetuses were not regarded as re-
search subjects locally in terms of having IRB protec-
tions, they appear to have at least been counted as
research subjects federally.
With Meyer-Bahlburg, New has also conducted a
few follow-up studies, mostly low-quality questionnaire
studies in which parents have been asked, long-distance,
to reply to a battery of questions. (The 2010 review
found these of such low quality, they did not even bother
to consider them for the meta-analysis, and Meyer-
Bahlburg has admitted that “fewer than 50% of mothers
and offspring have responded to questionnaires”
[Speiser et al. 2010b, under “3. Prenatal Treatment of
CAH”].) For these studies, the researchers had IRB
approval, but it does not appear that the families enrolled
in these studies would have known that they might have
been misled about the status of prenatal dexamethasone
when it was administered to the pregnant women. Thus
it is questionable whether their participation in the
follow-up study can be called fully informed.
So far as we can ascertain, New was not alone in her
less-than-rigorous approach to scientific study of prena-
tal dexamethasone for CAH. Indeed, although the inter-
vention has been offered in many other nations, Sweden
appears to be the only nation to have specifically re-
stricted prenatal dexamethasone for CAH to women
who agreed to participate in a continuous, prospective,
long-term study of the intervention, a restriction insti-
tuted there in 1999. (Before that it could be obtained
outside of trials.) The group has been led by Svetlana
Lajic, associate professor of molecular medicine and
surgery at the Karolinska University Hospital. In a re-
cent exchange with one of us (Feder), Lajic revealed that
the Swedish team has actually halted the intervention
part of the study due to concerns about adverse effects.
Lajic wrote to Feder that “due to our findingswe have
addressed the Regional Ethics Committee in Stockholm,
inNovember2010,andstatedthatdue topossibleadverse
events we wish to put on hold further recruitment of
patients to the on-going prospective study of prenatal
DEX treatment of CAH” (Lajic 2011). While our paper
was in press, the Swedish team published news of this
development, along with follow-up data on “43 children
treated in Sweden and Norway during 1985–1995”
(Hirvikoski et al. 2012, 1). When compared to controls,
[i]n general, treated children were born at term
and were not small for gestational age. As a
group, they did not exhibit teratogenous effects/
gross malformations, although eight severe ad-
verse events were noted in the treated group,
compared with one in the control group. Three
children failed to thrive during the first year of
life; in addition, one had developmental delay
and hypospadias; one had hydrocephalus; two
girls were born small for gestational age, and
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one of these girls was later diagnosed with men-
tal retardation; and one child had severe mood
fluctuations that caused hospital admission. In
the control group, only one child was admitted
because of Down’s syndrome (Hirvikoski et al.
2012, 2).
The Swedish team has clearly been alarmed by the
extraordinary number of serious medical problems
among the small group of children treated prenatally.
As for the cognitive and behavioral outcomes, in
their most recent report the Swedish team acknowl-
edged that “The small sample size, relatively high
refusal rate, and the retrospective study design limited
the conclusiveness of the results” of their follow-up of
the behavioral development in 40 Swedish children
treated prenatally. Nevertheless, they could report that
[a]n adverse effect was observed in the form of
impaired verbal working memory in CAH-
unaffected short-term-treated cases [i.e., the chil-
dren who were not the intended targets of the
intervention]. The verbal working memory ca-
pacity correlated with the children’s self-
perception of difficulties in scholastic ability,
another measure showing significantly lower
results in CAH-unaffected, DEX-exposed chil-
dren. These children also reported increased so-
cial anxiety. In the studies on gender role
behavior, we found indications of more neutral
behaviors in DEX-exposed boys (Hirvikoski et
al. 2012, 2).
In other words, the boys appeared relatively less
masculine—another unintended effect.
The Swedish team argued that “the[se] results cause
concern because no side effects should be tolerated in
CAH-unaffected children who do not benefit from the
treatment per se” (Hirvikoski et al. 2012, 2). Indeed,
the team concluded its 2012 report with as strongly a
worded ethics statement as has ever been issued by a
team engaged in the use of prenatal dexamethasone for
CAH: “We find it unacceptable that, globally, fetuses
at risk for CAH are still treated prenatally with DEX
without follow-up” (Hirvikoski et al. 2012, 2).
As we urged United States governmental agencies
in 2010, the Swedish team now “urge[s] the scientific
community to perform additional retrospective stud-
ies, preferably on all treated children and young
adults” (Hirvikoski et al. 2012, 2). Yet we see no signs
that rigorous, independently-audited, retrospective
studies will be pursued in the United States, where
the great majority of interventions appear to have
occurred, largely under the guidance of Maria New.
Although we find plenty of suggestions in New’s grant
materials and presentations that results from her retro-
spective follow-up studies are forthcoming, and al-
though the NIH repeatedly renewed her prenatal
dexamethasone research funding, little appears to have
been produced in terms of longer-term data on prenatal
dexamethasone for CAH, particularly with regard to
long-term safety. We can find no publications resulting
from New’s 2007 Rare Diseases Clinical Research
Network (RDCRN/NIH) follow-up study protocol,
except a paper she co-authored in a 2011 issue of
Advances in Experimental Medicine and Biology. This
paper purports to demonstrate the long-term safety of
prenatal dexamethasone for CAH. But the article con-
tains no methods section, no description of the study
allegedly being reported, no description of the con-
trols, nor even of the intervention. It consists simply of
unexplained tables of data and unsupported narrative
(New and Parsa 2011). Needless to say, it is not the
kind of report that will ever make it into a meta-
analysis.
Although New had told the U.S. government in
1996 “we propose to continue our studies of prenatal
diagnosis and treatment” (New 1996b, 61), we can
find no evidence of there ever having been, in the
United States, a reasonably-designed, IRB-approved,
prospective, long-term study—nothing like the rigor-
ous approach taken in Sweden. In a recent debate with
Dreger on this subject, Meyer-Bahlburg confirmed the
total absence of prospective continuous studies in the
United States and offered no indication that any has
ever even been planned (Meyer-Bahlburg 2011). This
is very concerning, and is even more worrisome when
one considers the design of New’s 2007 RDCRN/NIH
retrospective follow-up study (to be carried out with
Meyer-Bahlburg). As we discovered from our FOIA
requests, that protocol specifically states as an “exclu-
sion criteria for all groups” this: “mental impairment
which prevents understanding of questionnaire” (New
2007, 25).
So, while the researchers in Sweden are document-
ing cognitive impairment among those exposed to
prenatal dexamethasone for CAH, researchers in
America have specifically designed a follow-up study
that prevents detection of certain negative effects on
cognitive development.
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Promotion of Prenatal Dexamethasone for CAH
New has a clear track record of promoting the use of
prenatal dexamethasone for CAH as safe and effective
to clinicians who might reasonably have expected her
to represent accurately to them what was actually
known and unknown. In a co-authored article for the
2000 edition of the Cecil Textbook of Medicine, New
advised her colleagues: “Prenatal treatment with dexa-
methasone has been shown to be safe and effective for
both mother and child in the largest human studies”
(New and Josso 2000, 1302), implying that there were
large human studies of sufficiently high quality to
establish safety and efficacy. A few years later, New’s
discussion of prenatal dexamethasone (published with
two co-authors) in the 2007 edition of the textbook
Pediatric Endocrinology reads, “we believe that prop-
er prenatal treatment of fetuses at risk for CAH can be
considered effective and safe. Long-term studies on
the psychological development of patients treated pre-
natally are currently underway”—a tacit admission of
more interest in outcomes related to gender identity
and cognitive development than in metabolic out-
comes like those involving cardiovascular function
(New, Ghizzoni, and Lin-Su 2007, 237).
New’s determined influence on prenatal treatment
practices for CAH is also illustrated by the work she
has published in GeneReviews, the NIH-sponsored
free online textbook regarded as an authoritative
source in prenatal counseling. Until recently (for rea-
sons we explain below), New’s article described pre-
natal dexamethasone for CAH as if it were standard
practice, explaining precisely how clinicians in the
field could implement the intervention. No mention
was made of its experimental status, of the fact that the
use is off-label, nor of the absence of evidence for its
efficacy and safety (Nimkarn and New 2009; cf.
Witchel and Miller 2012).
In her grants with the NIH, New also represented
prenatal dexamethasone for CAH as having been
shown safe and effective. For example, in her 2003
report, she indicated: “Based on our experience and
other large human studies, proper prenatal diagnosis
and treatment of 21-OHD is safe for mother and child,
and is effective” (New 2003a, 98). In her NIH grant
materials, New used the fact that “[w]e are the only
group in the U.S.A. routinely carrying out prenatal
diagnosis and treatment of CAH” as a major reason
why the government should fund her studies on the
“large population of prenatally-treated infants” she
had “accumulated” (New 1996b, 2). Already by her
1996 report to the NIH, New was claiming her clinic
“receive[d] requests [for the intervention] from all
over the U.S. and foreign countries at the rate of 3–4
per week” (New 1996b, 61). A decade later, New’s
protocol for a follow-up study again indicated that her
clinic had been drawing patients from all over the
United States (New 2007, 25–26); recall that by
2006 she reported use of the intervention in 768 preg-
nancies (New 2006, 3).
The large draw of potential subjects for her grants
perhaps occurred because New actively promoted pre-
natal dexamethasone for CAH as safe and effective not
only to clinicians but also directly to parents, including
through the CARES Foundation, a non-profit organi-
zation dedicated to supporting individuals and families
with CAH and to advancing research and improved
clinical practices (e.g., newborn screening). New’s
2001 lecture to parents at CARES, quoted above,
represents one example. Another appears in the
CARES Foundation Winter 2003 newsletter, for
which Elizabeth Kitzinger of Weill Cornell Medical
College provided a short article effectively advertising
New’s clinic as the place to go for at-risk mothers:
In the United States, the only center routinely
offering prenatal diagnosis and treatment is Dr.
Maria New’s clinic at New York Presbyterian
Hospital-Weill Medical Center (Cornell) in
New York City. Dr. New has treated over 600
pregnant women at risk for the birth of a CAH-
affected child.… The results are remarkable. Dr.
New maintains contact with all children treated
prenatally, and has found no adverse develop-
mental consequences. Thus, with nearly
20 years’ experience, the treatment appears to
be safe for mother and child, though there are
endocrinologists who are wary of using dexa-
methasone prenatally even now (Kitzinger 2003,
¶2–¶3).
Some parents reading this might hear in that last
line a warning that not all clinicians were convinced
this use was safe and effective. But others might
reasonably read it as an indication that Dr. New would
be the only clinician willing to help them. The text
continues:
It is important to note that prenatal diagnosis and
treatment should ONLY be done in a clinic like
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Dr.New’swith longexperienceandcommitment to
follow-up. Only by tracking the growth of prena-
tally treated children can the long-term effects of
treatment be exhaustively studied. Administering
dexamethasone to achieve normal genitalia
requires the judgmentandexperienceofspecialists.
The benefits to families of classically affected girls
cannot be underestimated. We hope that the avail-
ability of this treatment will be shared with all
families at risk for the birth of CAH-affected chil-
dren. (Kitzinger 2003, ¶4, capitalization original).
Even since the 2010meta-analysis, the website of the
Maria New Children’s Hormone Foundation continues
to claim “the treatment has been found safe for mother
and child” (New 2010a, ¶4). In 2010, our complaints to
the FDA about advertisement of this off-label use as
“safe for mother and child” were referred to Robert
“Skip” Nelson, an FDA-based pediatrician and ethicist.
As mentioned above, our discussions with Nelson clar-
ified that regulations prohibit only two groups from
advertising off-label uses as “safe and effective”:
employees of a drug’s maker (which New is not) and
FDA-approved investigators of drugs.
According to Nelson, New did seek and obtain an
IND (investigational new drug) exemption from the
FDA in 1996 for prenatal dexamethasone for CAH; this
would mean she sought and obtained the FDA’s permis-
sion at that time for a specific study of this drug use. But
as Nelson explained to us, since New does not currently
have an approval from the FDA to study prenatal dexa-
methasone, she does not count as an FDA investigator,
so she is not currently prohibited from calling this
intervention “safe and effective.” In other words, be-
cause of a regulatory loophole in the United States, if
you inappropriately investigate an off-label use of a
drug, then you can also inappropriately advertise it—
even to pregnant women and even when the drug use is
meant to alter the course of fetal development.
Notably, we think Nelson may be incorrect in his
claim that in 1996 the FDA granted New an IND ex-
emption for the use of prenatal dexamethasone to pre-
vent sex atypicality in CAH. Through the FOIA, we
obtained the 1996 FDA letter cited by Nelson in 2010,
and it actually refers only to a “proposal to utilize
dexamethasone to treat pregnant women with a [sic]
congenital adrenal hyperplasia” (Sobel 1996). It is en-
tirely possible the 1996 letter referred to a study of the
use of dexamethasone to treat women with CAH who
became pregnant, i.e., an off-label use meant to treat a
woman herself afflicted with CAH to keep her healthy
during her pregnancy, an entirely different medical mat-
ter than an explicit attempt at fetal engineering wherein
the mother is merely a carrier of CAH. There appears to
be no evidence to support Nelson’s representation of the
1996 IND exemption letter.
AWorrisome Track Record
We feel optimistic that our efforts to draw attention to
this use of prenatal dexamethasone have increased the
likelihood that physicians and researchers will respect
the rights of the population exposed. Nevertheless, we
feel pessimistic about ever knowing what really hap-
pened to most of those already exposed—for weeks or
months of pregnancy or fetal development. Recall that
in 2002 a joint statement by the European and Amer-
ican pediatric endocrinology societies called for data
on prenatal dexamethasone outcomes to be entered
into “a central database audited by an independent
safety committee” (Joint LWPES/ESPE CAH Work-
ing Group 2002, 4049). But—except for a still unpub-
lished European study known as “PREDEX,” which
enrolled only 24 subjects from 1999 to 2004, includ-
ing subjects from the Swedish prospective cohort
(Lajic et al. 2004)—no such thing has happened. In-
stead, it appears from the 2007 RDCRN/NIH study
protocol that Maria New retains control of the data-
base of contact information for what she reports is
now more than 768 children and their mothers who
have been exposed to this prenatal intervention
through her clinics (New 2006, 3). It seems likely that
that population represents at least a significant minor-
ity of those exposed. In fact, New’s 2001 NIH “appli-
cation for continuation grant” provides a table
describing human subjects under the “specific [study]
aim” called “prenatal dx and treatment in families at
risk,” and there the total number of subjects is stated as
2,144 (New 2001b, 14).
Our research has caused us substantial concern
about what appears to be a pattern of misrepresenta-
tion by Maria New, even beyond what we take to be
misrepresentations regarding the status of prenatal
dexamethasone for CAH. As reported in The Wall
Street Journal in 2005, one of New’s NIH grants
(which included work on CAH) formed the subject
of a fraud suit brought against Weill Cornell Medical
College—a suit over “phantom studies” that resulted
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in a settlement whereby Cornell paid the government
$4.4 million (Wysocki 2005). While the settlement
required no admission of wrongdoing, it seems signif-
icant that, at the time of the fraud case, New’s status at
Cornell radically changed; substantial portions of her
Cornell titles and salary appear to have been adminis-
tratively withdrawn.2
An oblique exchange in which we participated in
2010 raises additional concerns about New’s track
record for trustworthiness. In a project aimed at mak-
ing known the experimental status of prenatal dexa-
methasone for CAH, Dreger wrote with Taylor Sale
(Dreger’s student and a genetic counselor) to the edi-
tors of GeneReviews to request that Dr. New’s article
in that publication be changed to reflect medical con-
sensuses concerning prescription of prenatal dexa-
methasone for CAH (Dreger and Sale 2010). The
editors reviewed the consensus statements Dreger
and Sale provided them and then wrote to New with
recommended changes. Some time later, one of the
editors wrote to Dreger and Sale to report that: “Dr.
New’s initial reply to our proposed edits to the 21-
hydroxylase deficient [sic] CAH GeneReview is that
‘Prenatal dexamethasone treatment has been FDA ap-
proved by Dr. Sobel.’” The editor added, “We are
interested in your thoughts on [Dr. New’s] comment”
(Dolan 2010). We informed the editors that Solomon
Sobel was the FDA physician who had signed off in
1996 on a single IND exemption (Sobel 1996). As we
surely did not need to explain to the GeneReviews
editors, this did not qualify prenatal dexamethasone
for CAH as “FDA approved.”
Today, New’s co-authored GeneReviews article on
21-OHD CAH says this: “Prenatal treatment should
continue to be considered experimental and should
only be used within the context of a formal IRB-
approved clinical trial” (Nimkarn and New 2010b, ¶1
under “Therapies Under Investigation”). Since the
2010 revision, the article no longer provides detailed
instructions on how to conduct the intervention. And
yet, the change reflected in the GeneReviews article
does not appear to mark a major change in approach
for New. Just after the revision of the GeneReviews
piece, New published a short article in The American
Journal of Bioethics entitled, “Vindication of Prenatal
Diagnosis and Treatment of Congenital Adrenal Hy-
perplasia with Low-Dose Dexamethasone.” There she
wrote: “The recent reports by the Office of Human
Research Protections and the FDA … make crystal
clear that my research on prenatal treatment of CAH is
and always has been both legally and ethically proper
at every level” (New 2010c, 68).
In spite of our petitions, the Office of Human Re-
search Protections (OHRP) appears to be quite a bit
less concerned than we are about the veracity of New’s
claims. For example, the agency appears to have ac-
cepted a claim that New had not been conducting fetal
experimentation with dexamethasone at Mount Sinai,
apparently without learning or considering that her
2006 NIH grant report described “gallop[ing] ahead”
with the intervention and specified, as part of her
“research progress report,” at least 27 fetuses exposed
to prenatal dexamethasone for CAH since New had
relocated her clinic to Mount Sinai (New 2006). As
part of its investigation following our letters, the
OHRP uncovered the deeply problematic IRB-
approved consent forms from Weill Cornell mentioned
above, yet the OHRP accepted New’s claims that
appropriate IRB oversight and informed consent had
occurred. The OHRP staff did not indicate in their
response to us how many of the pregnant women
New claims to have “treated” were even in IRB-
approved trials, nor did they address the problematic
disjuncture between her own advertisement of prenatal
dexamethasone as “safe for mother and child” and her
simultaneous federally funded study to investigate
whether in fact it is safe for mother and child.
This all seems particularly strange since Tamar-
Mattis’s research turned up two strongly-worded
2004 determination letters from the OHRP finding
major faults with New’s IRB-approved studies at Weill
Cornell (Tamar-Mattis 2010). (OHRP determination
letters are the final result of investigations that reveal
problems in the conduct of research.) New was not the
only researcher at Cornell named in the findings; in
2 On February 12, 2003, New wrote to the NIH asking for
money to support herself, under the NIH Merit Award system:
“As I am no longer Chairman of Pediatrics, Chief of Pediatric
Endocrinology, and Program Director of the CCRC, I have
much more time to devote to the research proposed in my Merit
Award. … This is a hard time for me and I am deeply apprecia-
tive of your consideration” (New 2003b). In a subsequent inter-
nal memo, the NIH staff “enthusiastically support[ed]” giving
New more money under the Merit Award system, without men-
tioning why “her circumstances changed abruptly this year when
she had to relinquish the chairmanship of the Department of
Pediatrics and the directorship of the Children’s Clinical Re-
search Center at Weill-Cornell Medical School and the salaries
entailed in these positions” (NIH Staff 2003). Shortly after, New
was hired by Mount Sinai School of Medicine.
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fact, the OHRP found the entire system for reviewing
pediatric research at Cornell so problematic that they
placed a restriction on Cornell’s Federalwide Assur-
ance and took the extraordinary step of requiring re-
view by the IRB of all active research involving
children (McNeilly 2004). The problems the OHRP
found with protection for subjects in New’s studies
were particularly alarming: an informed consent form
that did not include a description of the purpose of
research, as required (McNeilly 2004, 5); consent
forms that contained extremely complex language that
a subject would be unlikely to understand (McNeilly
2004, 6); an informed consent form that did not state
that “the tests conducted for the protocol could be
obtained outside the research” (McNeilly 2004, 5);
“subjects enrolled outside the protocol age range prior
to IRB review and approval” (McNeilly 2004, 4);
missing IRB records (McNeilly 2004, 3) and research
initiated without first obtaining legally informed con-
sent (McNeilly 2004, 3). The OHRP also noted that
Weill Cornell had suspended New’s research protocol
in the fall of 2002 but did not report the suspension to
the OHRP until June 2003 (McNeilly 2004, 4).
Why so much scrutiny of New and Weill Cornell by
the OHRP in 2004 and so little by the OHRP in 2010?
This seems to be part of a problematic trend forming at
the OHRP—again suggesting that prenatal dexametha-
sone for CAH is not a unique case but a bellwether. A
March 2011 analysis from the Report on Research
Compliance on the OHRP has found a substantial
drop-off of OHRP determination letters in the last
four years: “Agency observers and others expressed
concern about the steep drops in letters and open cases,
telling [the Report on Research Compliance] they raise
questions about the agency’s current commitment to
serious oversight of human subjects research and inves-
tigations into possible wrongdoing” (National Council
of University Research Administrators 2011, 1). Nota-
bly, the “possibility that compliance is increasing at
institutions was not among the reasons OHRP cited for
the drop, and funding is not a problem” (National Coun-
cil of University Research Administrators 2011, 1). Nor
has the number of complaints made to the OHRP fallen.
Final Thoughts
The OHRP and FDA have not yet fully responded to our
FOIA requests. (Dreger is presently suing to obtain the
remainder of the documents.) But even what we already
have found indicates that the government could well
have made a case for inappropriate behaviors here and
could have issued statements echoing at least some of
our concerns about the way that prenatal dexamethasone
for CAH has been administered and studied.
Despite the disappointing responses from the OHRP
and FDA, we do not regret raising the alarm as we did
starting in January 2010. Doing so increased awareness
among the affected population about the actual status of
prenatal dexamethasone and has also shone light into
corners we would not otherwise be able to view. For
example, it made available to the public New’s retro-
spective study protocol and IRB-approved consent
forms, and it also led to a reporter for Time magazine
finding women who indicated that they did not know,
when given prenatal dexamethasone to attempt preven-
tion of virilization in female fetuses, that it was an off-
label and controversial drug use (Elton 2010). Without
the investigation, this valuable information would have
remained hidden from view.
The investigation also seems to have driven Mount
Sinai to take action, judging from Silverstein’s re-
sponse to the OHRP:
The Committee [at Mount Sinai charged with
responding] determined that there are widely dif-
fering opinions amongst the staff, with some staff
members expressing significant concerns regard-
ing the use of dexamethasone for the prenatal
treatment of CAH. A particular concern is the
current necessity to treat potentially unaffected
fetuses until a diagnosis is determined. Therefore,
the Committee concluded that the clinical use of
dexamethasone in this situation should require a
rigorous informed consent process with detailed
documentation that the risks and benefits of this
treatment have been clearly communicated to the
parents making a decision to engage in prenatal
treatment. The Committee also recommends that
this issue be referred to the Medical Board of The
Mount Sinai Hospital for further consideration of
the consent issue. (Silverstein et al. 2010, 11).
It would appear, then, that Mount Sinai now shares
our concerns about the practices associated with the
administration of dexamethasone. Nevertheless, it is
still the case that the Maria New Children’s Hormone
Foundation website declares that prenatal dexametha-
sone for CAH “has been found safe for mother and
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child” and provides a phone number to call to make an
appointment (New 2010a, ¶4). When the number is
called, it rings to a clinic at Mount Sinai.
Epilogue
As our paper was in press, Maria New’s research group,
led by Meyer-Bahlburg, published a study including
some cognitive outcome data for 67 children prenatally
exposed to dexamethasone for CAH (Meyer-Bahlburg et
al. 2012). The children studied came from New’s data-
base (Meyer-Bahlburg et al. 2012, line 92) and included
eight CAH-affected girls whowere “long-term” exposed
in utero and 59 boys andCAH-unaffected girlswhowere
“short-term” exposed (Meyer-Bahlburg et al. 2012, line
23). These children were compared to 73 unexposed
controls (Meyer-Bahlburg et al. 2012, line 24).
The new paper concludes: “Our studies do not repli-
cate a previously reported adverse effect of short-term
prenatal DEX exposure on working memory, while our
findings on cognitive function in CAH girls with long-
term DEX exposure contribute to concerns about poten-
tially adverse cognitive aftereffects of such exposure”
(Meyer-Bahlburg et al. 2012, lines 34–36). The “previ-
ously reported adverse effect of short-term prenatal
DEX exposure” was that reported by the Swedish team
(Hirvikoski et al. 2007). But whereas the Swedish team
employed a relatively rigorous design (a prospective,
controlled, long-term study), in the new study from
New’s group, the 67 exposed children were selected
via convenience sampling performed retrospectively.
Furthermore, although the new Meyer-Bahlburg et
al. publication purports to seek information on the
effects of dexamethasone exposure (Meyer-Bahlburg
et al. 2012, lines 26–27), among the eight girls long-
term exposed the degree of exposure varies from a total
of nine weeks of fetal life to a total of 39 weeks (Meyer-
Bahlburg et al. 2012, lines 117–120), an exposure-
length difference of more than four times, making it
very difficult to establish meaningful dose-effect.
In marked contrast to the Swedish team, and as if to
confirm the weakness of the study by New’s group,
Meyer-Bahlburg et al. found some “positive” cognitive
outcomes in the short-term treated children. Understand-
ably, they found this hard to explain. (No one suspects
first-trimester glucocorticoid exposure at 60 to100 times
normal levels to be good for children’s brains.) In their
discussion, the authors try to explain the lack of
corroboration of their results by other studies or by logic
(Meyer-Bahlburg et al. 2012, lines 278–298), but they do
not propose the most obvious explanation for this very
strange finding: The paper’s study population is a highly
skewed sample.
We document here that New has claimed to have
“treated” somewherebetween600and2,144 fetuseswith
dexamethasone for CAH, yet her group is now reporting
cognitive outcomes ononly67children in her database, a
tiny fraction of thosewho ought to be available for study.
Furthermore, based on New’s claims to the public and to
her granting agencies, her efforts should have produced
between about 98 and 268 girls who were long-term
dexamethasone-exposed, yet here her group reports on
cognitive outcomes in only eight. Thus it would appear
that the children included in the new study fromMeyer-
Bahlburg et al. represent somewhere between only 3 and
12 percent of the population prenatally exposed to dexa-
methasone under New’s consultation.
What the new paper from Meyer-Bahlburg et al.
actually appears to replicate is our finding: that the
approach taken byNew and her collaborators to prenatal
dexamethasone for CAH has been so scientifically weak
as to be both clinically uninformative and profoundly
unethical, especially in light of the history of DES.
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